Results · Apr-Jun 2026
Orchid Pharma Q1 FY27 results
Sales grew 76% to ₹304 crore from ₹173 crore in Apr-Jun 2025.
Operating profit fell 1% to ₹14 crore, an operating margin of 4.6% (down 3.6 points from a year ago).
Net profit fell 78% to ₹3.2 crore from ₹14.9 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −17%, net profit −88%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 304.2 | 172.9 | +76% |
| Operating profit (EBITDA) | 14.0 | 14.2 | −1% |
| Operating margin | 4.6% | 8.2% | −3.6 pts |
| Net profit | 3.2 | 14.9 | −78% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.